GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Cyclically Adjusted Revenue per Share

Biocept (FRA:B00) Cyclically Adjusted Revenue per Share : €4,861.78 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Biocept Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biocept's adjusted revenue per share for the three months ended in Jun. 2023 was €0.525. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4,861.78 for the trailing ten years ended in Jun. 2023.

During the past 12 months, Biocept's average Cyclically Adjusted Revenue Growth Rate was -7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-06-08), Biocept's current stock price is €6.80. Biocept's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was €4,861.78. Biocept's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Biocept was 0.12. The lowest was 0.01. And the median was 0.03.


Biocept Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biocept's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Cyclically Adjusted Revenue per Share Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 790.16 725.21

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 894.95 906.85 725.21 769.02 4,861.78

Competitive Comparison of Biocept's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Biocept's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biocept's Cyclically Adjusted PS Ratio falls into.



Biocept Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biocept's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.525/128.7287*128.7287
=0.525

Current CPI (Jun. 2023) = 128.7287.

Biocept Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.000 98.790 0.000
201312 82.353 98.326 107.817
201403 117.647 99.695 151.910
201406 87.500 100.560 112.011
201409 50.000 100.428 64.090
201412 387.500 99.070 503.508
201503 139.000 99.621 179.613
201506 69.000 100.684 88.219
201509 147.000 100.392 188.493
201512 200.000 99.792 257.993
201603 198.000 100.470 253.689
201606 590.000 101.688 746.891
201609 933.000 101.861 1,179.096
201612 612.500 101.863 774.045
201703 787.000 102.862 984.905
201706 379.333 103.349 472.486
201709 310.667 104.136 384.035
201712 210.250 104.011 260.215
201803 109.000 105.290 133.265
201806 88.000 106.317 106.551
201809 72.556 106.507 87.694
201812 50.400 105.998 61.208
201903 27.455 107.251 32.953
201906 15.500 108.070 18.463
201909 18.026 108.329 21.420
201912 16.557 108.420 19.658
202003 4.981 108.902 5.888
202006 1.920 108.767 2.272
202009 12.595 109.815 14.764
202012 34.040 109.897 39.873
202103 32.708 111.754 37.676
202106 22.269 114.631 25.008
202109 28.947 115.734 32.197
202112 22.048 117.630 24.128
202203 32.224 121.301 34.197
202206 9.761 125.017 10.051
202209 1.794 125.227 1.844
202212 -1.515 125.222 -1.557
202303 1.072 127.348 1.084
202306 0.525 128.729 0.525

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biocept  (FRA:B00) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biocept's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.80/4861.78
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Biocept was 0.12. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biocept Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biocept's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (FRA:B00) Business Description

Industry
Traded in Other Exchanges
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines